肝癌术后辅助治疗中国专家共识(2023版)  

Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2023 edition)

作　　者：肝癌术后辅助治疗中国专家共识协作组 中国医师协会外科医师分会 中国抗癌协会肝癌专业委员会 中华医学会肿瘤学分会肝癌学组 樊嘉 陈波[3] 高杰[4] 郭荣平[5] 李桐 商昌珍 王锋 杨欣荣[9] Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma;Chinese College of Surgeons;Committee of Liver Cancer,Chinese Anti‐Cancer Association;Liver Cancer Group,Society of Oncology,Chinese Medical Association;Fan Jia(不详;Department of Liver Surgery and Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]不详 [2]复旦大学附属中山医院肝肿瘤外科&肝移植科复旦大学肝癌研究所,上海200032 [3]中国医学科学院肿瘤医院 [4]北京大学人民医院 [5]中山大学肿瘤防治中心 [6]四川大学华西医院 [7]中山大学孙逸仙纪念医院 [8]东部战区总医院秦淮医疗区 [9]复旦大学附属中山医院

出　　处：《中华消化外科杂志》2023年第4期437-448,共12页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金(82072715);上海市卫健委协同创新集群计划(2019CXJQ02)。

摘　　要：肝细胞癌(HCC)术后复发是影响患者术后长期生存的重要因素,目前尚无公认有效预防HCC术后复发转移的辅助治疗方案。以靶向药物、免疫检查点抑制剂为代表的系统抗肿瘤治疗和局部治疗单独或联合应用的辅助治疗策略正在积极探索中。肝癌术后辅助治疗中国专家共识协作组、中国医师协会外科医师分会、中国抗癌协会肝癌专业委员会、中华医学会肿瘤学分会肝癌学组组织相关领域专家,经过多次讨论、反复修订,最终形成《肝癌术后辅助治疗中国专家共识(2023版)》,旨在梳理HCC术后辅助治疗相关证据,结合临床实践,为临床医师开展术后辅助治疗提供更好的指导,提高HCC患者术后生存获益。Recurrence of hepatocellular carcinoma(HCC)after surgery is an important factor affecting the long‐term postoperative survival of patients.So far,there is no proven postoperative adjuvant therapy to prevent HCC recurrence and metastasis.Currently,alone or in combination using of systemic antitumor therapy,represented by targeted drugs and immune checkpoint inhibitors,and local therapies are under active investigation.Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma,Chinese College of Surgeons,Committee of Liver Cancer of Chinese Anti‐Cancer Association and Liver Cancer Group in Society of Oncology of Chinese Medical Association organize experts and scholars in related fields to discuss and revise for several times and finally formulate the Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma(2023 Edition),aiming to provide better guidance for clinicians to carry out postoperative adjuvant therapy on the basis of relevant evidence of HCC postoperative adjuvant therapy and clinical practice,so as to increase the survival benefits of HCC patients after surgery.

关 键 词：肝细胞癌 专家共识 手术切除 辅助治疗 系统性治疗 介入治疗 放射治疗 抗病毒治疗 

分 类 号：R735.7[医药卫生—肿瘤]